Trial Profile
An open, multicenter study of the Mechanism of Osimertinib Resistance in Chinese Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Jun 2018
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Jun 2018 New trial record